News|Articles|May 22, 2026
You Can Build AI In-House. But Should You?
Author(s)EVERSANA
Related Content
Trending on PharmExec
1
Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO
2
How Basket-Trials are Reshaping Drug Development Timelines
3
Parabilis Reaches $3.7 Billion Market Cap on Frist Day Listed on NASDAQ
4
The New Capital of Care in Rare Disease
5